Urinary Eicosanoid Metabolites in HIV-Infected Women with Central Obesity Switching to Raltegravir: An Analysis from the Women, Integrase, and Fat Accumulation Trial

Table 1

Baseline characteristics of subjects completing 24 weeks of follow-up and included in eicosanoid analyses, total and by study arm.

	Total (𝑁=37)		RAL (𝑁=17)		PI/NNRTI (𝑁=20)
Ethnicity
African-American	22 (59)		9 (53)		13 (65)
Hispanic	6 (16)		4 (24)		2 (10)
White	8 (22)		3 (18)		5 (25)
Asian	1 (3)		1 (6)		0 (0)
Age in years-median (range)	43 (26–57)		41 (26–51)		46 (31–57)
Weight (kg)	81.8 (73.9–105.0)		88.7 (81.0–105.0)		77.7 (71.7–97.0)
BMI (kg/m^2)	32.0 (28.0–36.5)		34.7 (28.8–37.6)		30.4 (27.7–35.4)
VAT (cm^2)	138 (100–154)		145 (105–154)		138 (93–154)
SAT (cm^2)	432 (343–605)		450 (381–687)		420 (342–587)
VAT : SAT	0.25 (0.21–0.38)		0.25 (0.22–0.36)		0.25 (0.20–0.42)
Total cholesterol (mg/dL)	188.0 (162.0–214.0)		179.0 (162.0–206.0)		199.0 (164.5–221.5)
Triglycerides (mg/dL)^c	118.0 (92.0–152.0)		116.0 (85.0–144.0)		129.0 (101.0–176.0)
LDL (mg/dL)	115.8 (93.0–128.0)		113.0 (103.0–123.0)		116 (89.0–138.1)
HDL (mg/dL)	49.0 (40.0–57.0)		47.6 (40.2–57.0)		49.1 (39.0–55.0)
Glucose (mg/dL)	87.0 (78.0–94.0)		84.0 (78.0–93.0)		88.5 (80.0–97.5)
Tobacco Use (Current)	16 (43)		4 (24)^a		12 (60)^a
Daily anti-inflammatory use^b	14 (38)		7 (41)		7 (35)
CD4 count (cells/uL)	558 (422–747)		563 (447–747)		553 (354–770)
Baseline ART regimen
PI	23 (62)		11 (65)		12 (60)
NNRTI	14 (38)		6 (35)		8 (40)
NRTI
Abacavir	8 (22)		3 (18)		5 (25)
Tenofovir	29 (78)		14 (82)		15 (75)
Urinary eicosanoids (ng/mg cr)	Median (IQR)	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)	Mean (SD)
F2-IsoP	2.14 (1.49–3.16)	2.70 (2.09)	2.41 (1.96–3.04)	2.59 (1.14)	1.89 (1.35–3.77)	2.79 (2.67)
PGE-M (𝑁=36)	8.07 (4.47–10.56)	9.35 (6.77)	5.95 (4.25–9.52)	7.35 (6.07)	9.37 (5.36–13.48)	10.80 (7.10)
PGI-M (𝑁=36)	0.10 (0.06–0.15)	0.12 (0.08)	0.07 (0.05–0.10)^c	0.08 (0.04)	0.13 (0.08–0.21)^c	0.15 (0.09)
TxB2	0.46 (0.25–0.73)	0.53 (0.36)	0.34 (0.14–0.70)	0.45 (0.37)	0.55 (0.29–0.77)	0.60 (0.34)

Values shown are 𝑁 (percentage), median (interquartile range [IQR]), or mean (standard deviation [SD]) except where noted.
^aFisher’s exact 𝑃=0.045 for immediate versus delayed arm. ^bSeven women in each arm reported daily anti-inflammatory medication use: six in each arm reported non-steroidal anti-inflammatory drug use; one in the RAL arm reported taking celecoxib, and one in the PI/NNRTI arm reported taking aspirin 81 mg. ^cMann-Whitney 𝑈   𝑃=0.005 for RAL versus PI/NNRTI arm.
Abbreviations: ART = antiretroviral therapy; BMI = body mass index; F₂-IsoP = F₂-isoprostanes; HDL = high density lipoprotein cholesterol; LDL = low density lipoprotein cholesterol; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-NRTI; PI = protease inhibitor; PGE-M = prostaglandin E₂ metabolite; PGI-M = prostacyclin metabolite; RAL = raltegravir; SAT = subcutaneous adipose tissue; TxB₂= thromboxane B₂; VAT = visceral adipose tissue.